Keppra (levetiracetam) is primarily approved for treating partial-onset seizures, myoclonic seizures in epilepsy, and generalized tonic-clonic seizures [1]. However, it is also used off-label for other neurological conditions, including various types of epilepsy not explicitly listed in its approved indications [2].
What other conditions might Keppra be used for?
Doctors may prescribe Keppra for seizure types such as absence seizures or Lennox-Gastaut syndrome, even if these are not FDA-approved uses [2]. It has also been explored for conditions beyond epilepsy.
What is the evidence for Keppra's effectiveness in off-label uses?
Research continues to investigate Keppra's potential benefits in areas beyond its current approvals. For instance, studies have examined its use in status epilepticus, a medical emergency where seizures do not stop [3]. The drug's efficacy and safety in these off-label scenarios are evaluated through ongoing clinical trials and observed patient outcomes [3].
Are there any risks associated with using Keppra off-label?
Using any medication off-label carries potential risks, as the safety and efficacy may not have been as extensively studied as for approved indications. Patients prescribed Keppra for off-label uses should discuss potential side effects with their healthcare provider [1]. Common side effects of Keppra can include drowsiness, dizziness, and behavioral changes [4].
When does Keppra's patent expire?
The primary patent for Keppra has expired [5]. This means that generic versions of levetiracetam are available on the market [5].
What are the alternatives to Keppra for seizure control?
Numerous antiepileptic drugs are available as alternatives to Keppra, including lamotrigine, valproate, and carbamazepine [6]. The choice of medication depends on the specific type of epilepsy, the patient's medical history, and potential drug interactions [6].
Where can I find more information about drug patents?
Information regarding drug patents, including expiry dates, can be found on DrugPatentWatch.com [5].
Citations
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021287s037,021302s018,021359s020lbl.pdf
2. https://www.ncbi.nlm.nih.gov/books/NBK551604/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585615/
4. https://www.mayoclinic.org/drugs-supplements/levetiracetam-oral-route-parenteral-route/side-effects/drg-20074460
5. https://drugpatentwatch.com/
6. https://www.epilepsy.com/treatment/drugs-seizures